Navigation Links
Gene expression test reveals ER and HER-2 status of breast tumors

Two critical characteristics of breast cancer that are important to treatment can be identified by measuring gene expression in the tumor, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in Lancet Oncology online.

Researchers developed and validated a new genomic microarray test that identifies whether a tumor's growth is fueled by the female hormone estrogen and the role of a growth factor receptor known as HER-2 that makes a tumor vulnerable to a specific drug. The status of these factors is now determined by pathology tests.

"This is one important step towards personalized diagnosis and treatment planning based on an integrated genomic test of an individual tumor," said senior author W. Fraser Symmans, M.D., associate professor in the M. D. Anderson Department of Pathology. The Lancet Oncology paper results are the latest in an effort by the research team to develop a single test to quickly and efficiently determine the characteristics and vulnerabilities of a patient's breast cancer and ultimately to guide treatment.

About 70 percent of breast cancers are estrogen-receptor positive and another 15 to 25 percent are human epidermal growth factor receptor-2 (HER-2) positive. Each receptor status requires different types of treatment.

The gene expression tests were 90 percent accurate for both receptors, which makes them comparable to, if not better than, existing pathology tests.

"This moves us closer to developing an integrated single genomic test that could estimate the risk of cancer relapse after surgery, determine the ER and HER2 receptor status, and also gauge the sensitivity of the tumor to hormone therapy and chemotherapy," says Lajos Pusztai, M.D., Ph.D., associate professor in the M. D. Anderson Department of Breast Medical Oncology, and team leader with Symmans.

ER-positive tumors are treated with estrogen-suppressing drugs such as Tamoxifen. Tu mors that are HER-2 positive are sensitive to Herceptin, an antibody-based drug that binds to the HER-2 receptors, blocking them from coupling with growth factors that fuel breast cancer.

Last fall, the group published a study showing that a genomic microarray test can also predict a patient's response to chemotherapy. They also presented a paper in December showing that another genomic index predicts how an ER-positive patient will respond to hormonal therapy.

A prospective clinical trial will soon open at M. D. Anderson to use these tests to recommend treatment for patients with newly diagnosed stage I-III breast cancer.

In the Lancet Oncology paper, they employed an Affymetrix microarray to gather estrogen receptor and HER-2 receptor gene expression data from 495 breast cancer samples from seven institutions. The samples included both fine needle aspiration biopsies and traditional biopsies.

The team used 195 fine-needle biopsy samples to set gene expression thresholds that predicted ER-positive status with 90 percent accuracy and HER-2-positive status with 93 percent accuracy. They then applied those thresholds to two more validation studies involving the remaining samples, which showed that the initial results were both reliable and reproducible.

The gene expression tests disagreed with traditional immunohistochemical lab analysis of the tumors by 8 percent for ER and 11 percent for HER-2. The researchers note this degree of discrepancy is usual when different diagnostic methods are applied to the same samples.


'"/>

Source:University of Texas M. D. Anderson Cancer Center


Related biology news :

1. Alcohols effects on gene expression in the central nervous system
2. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
3. Towards precise classification of cancers based on robust gene functional expression profiles
4. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
5. Study: homemade gene expression technology unreliable
6. Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression
7. Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays
8. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
9. Computational verification of protein-protein interactions by orthologous co-expression
10. Random gene expression may drive HIV into hiding
11. Confirmation of human protein interaction data by human expression data
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... LEXINGTON, Mass. , March 22, 2017   ... collections, today announced that Doctors Pathology Service ... mid-Atlantic region of the United States ... the Delaware Health Information Network (DHIN) to ... researchers. The novel program, announced in ...
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
Breaking Biology Technology: